Tuesday, July 27, 2021

Tag: hematology

#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma

Kathleen Lau -
0
Read more

#VisualAbstract Obesity and body weight was not correlated with survival outcomes in patients with relapsed/refractory large B-cell lymphoma treated with CAR T-Cell therapy

Kathleen Lau -
0
Read more

#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia

Kathleen Lau -
0
Read more

#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma

Kathleen Lau -
0
Read more

#VisualAbstract Post-transplant cyclophosphamide is associated with increased incidence of cytomegalovirus infection in hematopoietic cell transplant recipients

Kathleen Lau -
0
Read more

#VisualAbstract Changes in minimal residual disease status is associated with risk of disease progression in patients with multiple myeloma

Kathleen Lau -
0
Read more

Ibrutinib plus Venetoclax show promising results for first-line treatment of chronic lymphocytic leukemia

Andréa Rondeau-Brown -
0
Evidence Rating Level: 2 (Good)  1. Combination therapy of Ibrutinib and Venetoclax may be successful first-line treatments for patients with Chronic Lymphocytic Leukemia (CLL) who are currently not undergoing treatment  2. This combination therapy had a 3-year progression free survival (PFS) of 93% in first line treatment of CLL  The evolution and...
Read more

#VisualAbstract Reduced-dose lenalidomide regimen significantly prolongs event-free survival in elderly, intermediate-fit patients with newly diagnosed multiple myeloma

Kathleen Lau -
0
Read more

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

Kathleen Lau -
0
Read more

#VisualAbstract Phase 3 trial shows adding clarithromycin to standard therapy does not improve progression-free survival in patients with multiple myeloma ineligible for autologous transplant

Kathleen Lau -
0
Read more
123...7Page 1 of 7
© Copyright 2 Minute Medicine, Inc. All rights reserved.